LOS ANGELES, CA--(Marketwired - Jun 1, 2017) - End
Post# of 416
The study is the first of several currently planned studies targeting inflammatory pathologies of renal origin, including ischemia/reperfusion injury, acute kidney injury and diabetic nephropathy.
"We are excited to start our work on kidney disease and further expand our pipeline of non-invasive therapies targeting vascular diseases and inflammatory conditions in vital organs," commented Endonovo CEO, Alan Collier.
Endonovo Therapeutics, Inc. (ENDV) Stock Research Links
Never argue with stupid people, they will drag you down to their level and then beat you with experience.
Get .... PrivacyLok https://cyberidguard.com/
Try SafeVchat: https://cyberidguard.com/
My comments are only my opinion and are not to be used for investment advice.
Please conduct your own due diligence before choosing to buy or sell any stock.